BioNTech SE (LON:0A3M)

Market Cap	19.49B -16.2%
Revenue (ttm)	2.75B +3.7%
Net Income	-498.93M
EPS	-2.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	853
Average Volume	15,099
Open	109.50
Previous Close	108.91
Day's Range	106.33 - 110.00
52-Week Range	80.00 - 125.70
Beta	1.51
RSI	46.96
Earnings Date	Mar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 6,772
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3M

Financial Performance

Financial numbers in EUR